Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Fruquintinib × raltitrexed × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 12 Rectal Neoplasms 9 Colonic Neoplasms 5 Unspecified Adult Solid Tumor, Protocol Specific 2 Stomach Neoplasms 2 Thrombocytopenia 1 Squamous Cell Carcinoma of Head and Neck 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Mesothelioma, Malignant 1 Liver, Cancer of, Primary Resectable 1 Inoperable Esophageal Cancer Stage I-III 1 Hepatocellular Carcinoma Resectable 1 Hepatecellular Carcinoma 1 Head and Neck Squamous Cell Cancer 1 Fruquintinib 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Cancer Metastatic 1 Colon Cancer Liver Metastasis 1 Carcinoma, Hepatocellular 1 Advanced Metastatic Colorectal Cancer 1 Advanced Gastric Cancer 1 Advanced Colorectal Carcinoma 1 Advanced Colorectal Cancer 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 Irinotecan 1 HMPL-013 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡